Company Analysis
Sign in

Aktis Oncology, Inc. (AKTS)

Nasdaq: AKTS · Pharmaceutical Preparations · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.8
◀ Past 6.0● Present 6.6▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202659
Newest filingNov 12 · 10-Q
Annual reportMar 30, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$3.2M
Insider buys, 12 months$59.2M
Patents granted1
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 24, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Jul 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 20, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AKTS · research, not advice